Sequent Scientific Ltd (VIYASH) Q1FY27 Management Mirror - Jun-2026 Qtr
Revenue Reaches Rs 946 Crores in Jun'26 Qtr; Double-Digit Growth Guided with $1 Billion Target for FY32
Management has maintained a focus on achieving a sustainable annual revenue growth rate of 15% as guided in the Mar'26 Qtr concall. In the Jun'26 Qtr, consolidated revenue was reported at Rs 946 crores (stated as Rs 9,464 million in financial results), representing a YoY growth of 19.5% and a QoQ growth of 2.9%. Management reaffirmed expectations for sustained double-digit revenue growth. Additionally, a long-term aspiration was initiated to achieve $1 billion in revenue by 2032 (FY32), implying an approximate 18% CAGR from Q1'27 levels. The CDMO business, which was projected in the Dec'25 Qtr to reach Rs 70 crores to Rs 90 crores for that fiscal year, was guided in the Mar'26 Qtr to grow 30% to 40% in FY27, built on an existing base of approximately Rs 200 crores to Rs 225 crores. The European Union operations, after seeing flat revenue in Euro terms in Jun'26 Qtr due to contract phasing, are guided to return to an annual growth rate of 18% to 20% on an INR basis.
7 more themes on the ELITE plan.